Antidepressants in long-term migraine prevention

Area of Science:

• Neuroscience
• Pharmacology
• Psychiatry

Background:

• Migraine and depression frequently co-occur in 20-30% of patients.
• Antidepressants, particularly tricyclics, demonstrate efficacy in migraine prevention despite not being first-line for migraine alone.
• Monotherapy with antidepressants is often insufficient for managing both conditions concurrently.

Purpose of the Study:

• To review the efficacy of antidepressants in migraine prevention.
• To present recommended drug combinations for patients with comorbid depression and migraine.
• To discuss the pharmacological mechanisms and potential interactions of these treatments.

Main Methods:

• Review of clinical trials on antidepressant efficacy in migraine.
• Analysis of pharmacological mechanisms of antidepressants and related drugs.
• Examination of drug interaction profiles for combination therapies.

Main Results:

• Antidepressants are effective for migraine prophylaxis.
• Combination therapies involving antidepressants, newer agents, and established migraine preventatives (e.g., beta-blockers, topiramate, sodium valproate) are often necessary.
• Acute migraine medications (triptans, ergotamines, analgesics) are frequently combined with preventive strategies.

Conclusions:

• Combination therapy is essential for effectively treating patients with both migraine and depression.
• Understanding neurotransmitter systems (serotonin, dopamine, norepinephrine, CGRP) is key to selecting appropriate treatments.
• Awareness of drug interactions is vital to avoid undertreatment and improve patient outcomes.